1、1EXECUTIVE INSIGHTSL.E.K.Consultings Look at Key Trends in Pharma Services for 2023IntroductionBiopharma organizations face an increasingly complex landscape as new technologies,platforms and patient expectations necessitate innovation throughout the ecosystem,from R&D through commercialization and

2、manufacturing.Trial volume has increased across the industry,with particularly strong growth in certain therapeutic areas and modalities like oncology and specialty drugs.Yet operational hurdles stemming from the growing complexity of trials,such as the volume of data and the number of endpoints and

3、 geographies,will require pharmaceutical companies to enhance their capabilities across the trial workflow in areas like data collection,regulatory operations and patient recruitment.The broader biopharma landscape has evolved from high-volume blockbusters to diffuse low-volume,high-value drugs like

4、 rare disease and specialty drugs.This shift has altered both the size and structure of trials and the challenges that occur across a products life cycle,from early R&D through commercialization and manufacturing support,requiring pharmaceutical services companies to evolve in tandem(see Figure 1).A

5、s stakeholders respond to this shifting dynamic,forward-thinking pharmaceutical services organizations have strategic opportunities to drive differentiation and serve as critical partners to biopharma over the coming years,even in a mixed macroenvironment.Trial volumeComplexity(e.g.,trial design,ope

6、rations)Commercial landscapeWorldwide total trial volume has grown 1.25x over the span of five years*The volume of trials in emerging markets*has grown 2.17x over five years,*reflecting the increasingly global and complex nature of trials and oncology trial volume is growing at a particularly fast r